ReviewOrphanet journal of rare diseases2017
An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.
Review in Orphanet journal of rare diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 29 citations in OpenAlex.
- Systemic Immunomodulatory Therapy in Uveitis Related to Behçet's Disease: A 10-year Profile.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive Strategies.Medical science monitor : international medical journal of experimental and clinical research · 2024Review
- Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approaches.International ophthalmology · 2023Review
- [Frosted branch angiitis as first manifestation of Behçet's disease].Die Ophthalmologie · 2023Article
- Behçet uveitis: Current practice and future perspectives.Frontiers in medicine · 2022Review
- A review of ocular adverse events of biological anti-TNF drugs.Journal of ophthalmic inflammation and infection · 2020Review
- Behçet's Disease in Children: Diagnostic and Management Challenges.Therapeutics and clinical risk management · 2020Review
- Lessons of the month 2: A case of Behçet's disease: 70% have ophthalmic involvement.Clinical medicine (London, England) · 2019Article
- Epidemiology of Adult Uveitis in a Northern Ireland Tertiary Referral Centre.The Ulster medical journal · 2019Article
- Emerging Roles of Redox-Mediated Angiogenesis and Oxidative Stress in Dermatoses.Oxidative medicine and cellular longevity · 2019Review
- The use of biologic therapies in uveitis.Romanian journal of ophthalmologyReview
- Successful Treatment of Recurrent Oral and Genital Ulcers in Behcet's Disease with Rituximab.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ᅟ: Behçet's disease (BD) is a systemic vasculitis characterised by a relapsing remitting course, affecting multiple organ systems. In the eye, it is a cause of potentially blinding inflammation in the form of uveitis. Management of uveitis in BD often requires the use of systemic immunosuppression, in order to reduce disease activity and prevent accumulation of irreversible damage. Whilst corticosteroids remain the mainstay of treatment, long-term use is limited by the development of adrenocorticotrophic side effects. There has therefore been significant interest in the use of corticosteroid-sparing immunosuppressive agents, and more recently, biologic therapies. Recent publications have demonstrated biologic therapy to have beneficial effects both on overall disease control, and quality of life for patients with BD. Widespread use of such agents is however limited, partly by the lack of high quality research evidence, and partly by the prohibitive cost of biologic treatments. In this review, we discuss the most recent research investigating the use of biologic therapy in uveitis due to BD, with consideration of health economics and quality of life outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.